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Abstract Dystrophic neurites associated with amyloid
plaques precede neuronal death and manifest early in
Alzheimer’s disease (AD). In this work we have charac-
terized the plaque-associated neuritic pathology in the
hippocampus of young (4- to 6-month-old) PS1M146L/
APP751SL mice model, as the initial degenerative process
underlying functional disturbance prior to neuronal loss.
Neuritic plaques accounted for almost all fibrillar deposits
and an axonal origin of the dystrophies was demonstrated.
The early induction of autophagy pathology was evidenced
by increased protein levels of the autophagosome marker
LC3 that was localized in the axonal dystrophies, and by
electron microscopic identification of numerous autophagic
vesicles filling and causing the axonal swellings. Early
neuritic cytoskeletal defects determined by the presence of
phosphorylated tau (AT8-positive) and actin–cofilin rods
along with decreased levels of kinesin-1 and dynein motor
proteins could be responsible for this extensive vesicle
accumulation within dystrophic neurites. Although micro-
somal Ab oligomers were identified, the presence of
A11-immunopositive Ab plaques also suggested a direct role
of plaque-associated Ab oligomers in defective axonal
transport and disease progression. Most importantly, pre-
synaptic terminals morphologically disrupted by abnormal
autophagic vesicle buildup were identified ultrastructurally
and further supported by synaptosome isolation. Finally,
these early abnormalities in axonal and presynaptic struc-
tures might represent the morphological substrate of
hippocampal dysfunction preceding synaptic and neuronal
loss and could significantly contribute to AD pathology in the
preclinical stages.
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Introduction
Alzheimer’s disease (AD) gradually damages the function
and structure of particularly vulnerable brain areas, as those
used for memory and cognition. Accumulation of aggre-
gated proteins at the extracellular (amyloid-beta, Ab) and
intracellular (hyperphosphorylated tau) levels is one of the
major abnormalities found in the brain of AD patients
(revised in [13, 26, 50]). Another key pathological feature,
that defines this disease, is the early appearance of amyloid
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plaque-associated neuritic changes in the form of dystro-
phic neurites, together with a selective loss of connections
and neuronal groups. Dystrophic neurites, defined as
thickened or irregular neuronal processes, are considered to
be an expression of a widespread alteration of the neuronal
cytoskeleton. In AD, dystrophic axons are particularly
abundant in the hippocampal fiber systems originating
from the subiculum, CA1, and the entorhinal cortex [57].
Synaptic loss in both the neocortex and the hippocampus is,
so far, the best pathological correlate of early cognitive
decline [19, 41, 52–54, 59, 61]. The initial neuritic
degenerative changes may represent an early manifestation
of axonal damage that precede the appearance of synaptic
loss and, therefore, a promising disease-modifying mor-
phological target for early intervention strategies to reverse
the damage and rescue the deteriorating neurons. Sup-
porting the idea that these changes could be potentially
reversible, a recent study has reported that dystrophic
axons surrounding amyloid plaques remain connected
to viable neuronal bodies over a relatively long period of
time [1].
The expression of the human amyloid precursor protein
(APP) with single or double mutations in transgenic mouse
lines leads to the formation of neuritic plaques with clusters
of dystrophic neurites and glial recruitment that resembles
the amyloid pathology seen in AD brains [4, 28]. After
plaque formation, neuritic abnormalities progressively
develop as shown by in vivo multiphoton imaging in an
AD model [42]; however, the cellular dysfunction under-
lying the neuritic pathology is not well understood.
Numerous autophagic vacuoles accumulate within dystro-
phic neurites in the brains of humans with AD and AD
models [46, 47, 66] and several lines of investigation
support the notion that defects in the autophagy process, a
cellular catabolic mechanism essential for the degradation
of aggregated proteins and organelles, significantly con-
tributes to AD pathogenesis [11, 37, 46, 48]. Interestingly,
it has been reported that autophagic compartments partic-
ipate in APP processing and Ab peptides production [65,
66] suggesting a possible causal relationship between pla-
que formation and neuritic dystrophy. Remarkably,
restoring the intracellular autophagy pathway ameliorates
disease progression and cognition deficits in a transgenic
model [65] proving the potential therapeutic value of
autophagy induction in early stages of the disease for
neuronal function recovery.
Here, in this work, we have characterized the morpho-
logical and subcellular abnormalities associated with
dystrophic neurites around plaques in the hippocampus of
our PS1/APP model at 4–6 months of age. Such neuritic
abnormalities may result in defects in maintaining axonal
and synaptic terminals structure and function. As we have
reported previously, this bigenic model reproduces major
amyloid-induced pathogenic steps seen in humans. The most
relevant feature of our model is that, unlike many other
transgenic mice in which neuronal loss is not observed, the
selective neurodegenerative phenotype with specific subsets
of interneurons and pyramidal neurons is affected in hippo-
campus and entorhinal cortex, following a regional and
temporal pattern [5, 29, 44, 51]. This neuronal loss was found
to be associated with a neurotoxic inflammatory response
induced by soluble oligomeric Ab peptides [29]. A better
understanding of the pathological basis of the neuritic
changes, prior to neuronal loss in this model, will provide
valuable insights into the potential causes of early axonal
damage and synaptic dysfunction and will further improve
the accuracy of preclinical evaluation of novel therapeutic
agents intended to reverse axonal damage.
Materials and methods
Transgenic mice
The generation and characterization of PS1/APP transgenic
(tg) mice has been reported previously [5, 10, 12, 29, 30,
44, 51]. These double transgenic mice (C57BL/6 back-
ground) were obtained by crossing homozygotic
PS1M146L transgenic mice with heterozygotic Thy1-
APP751SL (Swedish: K670N, M671L and London: V717I
FAD mutations) mice (Charles River, France). Mice rep-
resented F6–F10 offspring of heterozygous transgenic
mice. Non-transgenic mice of the same genetic background
and ages were used as controls. All animal experiments
were carried out in accordance with the European Union
regulations and approved by the committee of animal use
for research at Malaga University.
Antibodies
The following primary antibodies were used in this study:
anti-human amyloid precursor protein (hAPP) rabbit
polyclonal (1:20,000, Sigma A8717); anti-Ab (clone 6E10)
mouse monoclonal (1:5,000, Sigma A1474); anti-oligomer
A11 (recognizes Ab42 oligomers but not monomers or
fibrils) rabbit polyclonal (1:500; Millipore AB9234); anti-
Ab42 rabbit polyclonal (1:40; Biosource 44-344); anti-
phospho-PHF-tau pSer202/Thr205 mouse monoclonal
(clone AT8) (1:500; Pierce MN1020); anti-cofilin rabbit
polyclonal (1:2,000, Cytoskeleton ACFLO2); anti-micro-
tubule-associated protein 1 light chain 3 (LC3) goat
polyclonal (1:1,000; Santa Cruz Biotechnology Sc16755);
anti-neurofilament 150 kDa rabbit polyclonal (1:5,000;
Millipore AB1981); anti-microtubule-associated protein 2
(MAP-2); rabbit polyclonal (1:5,000; Chemicon Ab5622);
anti-synaptophysin rabbit polyclonal (1:1,000; Abcam
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ab14692); anti-vesicular GABA transporter (VGAT) gui-
nea pig polyclonal (1:5,000; Calbiochem 676780); anti-
vesicular glutamate transporter (VGLUT1) guinea pig
polyclonal (1:10,000; Millipore AB5905); anti-human Ab,
N terminus (clone 82E1) mouse monoclonal (1:1,000, IBL
10323); anti-kinesin heavy chain (clone KN-01) mouse
monoclonal (1:1,000, Abcam AB9097); anti-dynein,
74 kDa (clone 74.1) mouse monoclonal (1:1,000, Millipore
MAB1618).
Tissue preparation
After deep anesthesia with sodium pentobarbital (60 mg/
kg), 2-, 4- and 6-month-old control (WT), PS1 and PS1/
APP tg mice were perfused transcardially with 0.1 M
phosphate buffered saline (PBS), pH 7.4 followed by 4%
paraformaldehyde, 75 mM lysine, 10 mM sodium me-
taperiodate in 0.1 M phosphate buffer (PB), pH 7.4. Brains
were then removed, post-fixed overnight in the same fixa-
tive at 4C, cryoprotected in 30% sucrose, sectioned at
40 lm thickness in the coronal plane on a freezing
microtome and serially collected in wells containing cold
PBS and 0.02% sodium azide.
For electronic microscopy, 4.5-month-old PS1/APP tg
mice were perfused transcardially with 0.1 M phosphate
buffered saline (PBS)/1% heparin, pH 7.4 followed by 2.5%
glutaraldehyde–2% paraformaldehyde in 0.1 M phosphate
buffer (PB), pH 7.4. After being removed, the brains were
post-fixed in the same fixative overnight at 4C, washed
several times with PB, sectioned at 50 or 100 lm thickness in
the coronal plane on a vibratome (Leica VT1000M) and
serially collected in wells containing cold PB and 0.02%
sodium azide. Then, the 100-lm sections were fixed in 2%
osmium tetroxide in 0.1 M PB and dehydrated, to be finally
embedded in Araldite (EMS, USA). Tissue blocks were cut
serially into semithin (1.5 lm) with a diamond knife in a
Leica ultramicrotome (EM UC6), placed on slides, stained
with 1% toluidine blue and explored with the light micro-
scope for amyloid plaques. Then, selected areas from
semithins were cut in ultrathin sections. Ultrathin sections
were placed on Formvar-coated grids and stained with uranyl
acetate and lead citrate before being examined with an
electron microscope (FEI Tecnai Spirit, OR, USA).
Light microscopy immunohistochemistry
Serial sections from control (WT) and both tg mice (PS1 and
PS1/APP) were processed in parallel for light microscopy
immunostaining using the same batches of solutions to
minimize variability in immunohistochemical labeling
conditions. Free-floating sections were first treated with 3%
H2O2/10% methanol in PBS, pH 7.4 for 20 min to inhibit
endogenous peroxidases, and with avidin–biotin Blocking
Kit (Vector Labs, Burlingame, CA, USA) for 30 min to
block endogenous avidin, biotin and biotin-binding proteins.
Sections were immunoreacted with one or two of the primary
antibodies over 24 or 48 h at room temperature. The tissue-
bound primary antibody was then detected by incubating for
1 h with the corresponding biotinylated secondary antibody
(1:500 dilution, Vector Laboratories), and then followed by
incubating for 90 min with streptavidin-conjugated horse-
radish peroxidase (Sigma–Aldrich) diluted 1:2,000. The
peroxidase reaction was visualized with 0.05% 3-3-diam-
inobenzidine tetrahydrochloride (DAB, Sigma–Aldrich),
0.03% nickel ammonium sulphate and 0.01% hydrogen
peroxide in PBS. After DAB, sections immunolabeled for
APP, MAP-2, neurofilament or synaptophysin were incu-
bated 3 min in a solution of 20% of Congo red. Sections were
then mounted on gelatine-coated slides, air dried, dehydrated
in graded ethanol, cleared in xylene and coverslipped with
DPX (BDH) mounting medium. Specificity of the immune
reactions was controlled by omitting the primary antisera.
For double immunofluorescence labelings, sections were
first sequentially incubated with the indicated primaries
antibodies followed by the corresponding Alexa488/568
secondary antibodies (1:1,000; Invitrogen). APP-immuno-
labeled sections were stained with 0.02% thioflavine-S in
50 ethanol for 5 min. Sections processed for immunoflu-
orescence were mounted onto gelatin-coated slides,
coverslipped with 0.01 M PBS containing 50% glycerin
and 3% triethylenediamine and then examined under a
confocal laser microscope (Leica SP5 II).
Immunoelectron microscopy
Sections of 50 lm from 4.5-month-old PS1/APP mice were
first washed with PBS and incubated in a 50 mM glycine
solution 10 min in order to increase the antibody-binding
efficiency. Following the standard immunohistochemical
protocol, the tissue was incubated overnight in primary
rabbit polyclonal antibodies anti-hAPP or anti-Ab42 in a
PBS 0.1 M/0.01% Tx-100/1% BSA solution at room tem-
perature. Then, they were washed in PBS, and incubated
with 1.4 nm gold-conjugated secondary antibody goat anti-
rabbit IgG (1:100; Nanoprobes) for one night at room
temperature. After postfixing with 1% glutaraldehyde and
washing with 50 mM sodium citrate, the labeling was
enhanced with the HQ Silver
TM
Kit (Nanoprobes). In neg-
ative control experiments, primary antibody was omitted.
Then, the slices were processed by the standard fixation,
dehydration and embedding steps.
Stereological analysis
Density and size of 6E10-positive amyloid plaques were
obtained by stereology-based quantification in the
Acta Neuropathol (2012) 123:53–70 55
123
hippocampal formation of PS1/APP at 6 and 18 months of
age (n = 4/age; 5 sections per animal) according to the
optical fractionator method as previously described [44].
Briefly, an Olympus BX61 microscope and the NewCAST
software package (Olympus, Glostrup, Denmark) were
used. In order to obtain the plaque density, the number of
plaques was quantified in five sections through the antero-
posterior extent of the hippocampus and then divided
between the sampled areas. CA1 subfields were defined
using a 109 objective and the number of plaques was
counted using a 409 objective. The number of counting
frames varied with the hippocampal region or subfield
layer analyzed. We used a counting frame of 7,154.7 lm2
with step lengths of 84.58 9 84.58 lm. Neurite and plaque
sizes were estimated by the nucleator application with
isotrophic probes (n = 5 radii). The number of APP-posi-
tive dystrophic neurites per plaque was quantified over
Congo red stained Ab deposits. Each analysis was done by
a single examiner blinded to sample identities.
Total protein extraction and Western blots
The protein pellets, obtained using the TripureTM Isolation
Reagent, were resuspended in 4% SDS and 8 M urea in
40 mM Tris–HCl, pH 7.4 and rotated overnight at room
temperature. The protein content was evaluated using
Lowry.
Western blots were performed as described previously
[12, 29, 51]. Briefly, 10–20 lg of protein from the different
samples were loaded on 16% SDS-Tris-Tricine-PAGE and
transferred to nitrocellulose (Hybond-C Extra, Amersham,
Sweden). After blocking, the membranes were incubated
overnight, at 4C, with the appropriate antibody. The
membranes were then incubated with anti-mouse horse-
radish-peroxidase-conjugated secondary antibody (Dako,
Denmark) at a dilution of 1/8,000. The blots were devel-
oped using the ECL-plus detection method (Amersham,
Sweden). For quantification, the scanned (Epson 3200)
images were analyzed using PCBAS program. In each
experiment, the intensity of bands from WT mice and/or
experimental condition were averaged and considered as 1
relative unit. Data were always normalized by the specific
signal observed in 6-month-old WT group.
Synaptosomes and microsomes preparation, soluble
fractions isolation and immunoprecipitation
The synaptosomal fractions were obtained basically as
described previously [62]. Briefly, the tissue was homog-
enized (using a Dounce homogenizer) in 0.32 M Sucrose,
10 mM Tris–HCl (pH 7.4) buffer (buffer A) containing
complete protease and phosphatase inhibitor cocktails
(Sigma). After homogenization, the crude synaptosomal
fraction (synaptosomes plus mitochondria) was isolated by
two sequential centrifugations (1,5009g, 10 min followed
by 12,5009g, 20 min; at 4C). The crude synaptosomes
were resuspended in 13% (final concentration) Ficoll 400
(in buffer A) and layered on the bottom of a discontinuous
gradient, composed by buffer A and 7% Ficoll (in buffer
A). The gradients were centrifuged at 100,0009g (45 min
at 4C) and the synaptosomes were isolated at the 7.5–13%
interface. After washing (twice with buffer A), the protein
content of the synaptosomal fractions was quantified by
Lowry.
The soluble and microsomal fractions (supernatant and
pellet, respectively) from PS1/APP and WT mice were
obtained after centrifugation at 100,0009g (1 h, 4C) as
described previously [29, 30].
The A11 or 6E10 immunoprecipitation experiments
were also performed as described in detail previously [29,
30]. Since the epitope recognized by A11 was sensitive to
detergents, synaptosomes and microsomes were disturbed
by sonication (4 pulses at 100 W, 30 s at 4C). After
sonication, the synaptosomes and microsomes were cen-
trifuged (30,0009g, 30 min at 4C) and soluble proteins
were used for immunoprecipitation. A11 and 6E10
immunoprecipitation was done using 50 lg of soluble
protein.
Statistical analysis
Data was expressed as mean ± SD. The comparison
between two mice groups (WT and PS1/APP mice or PS1
and PS1/APP tg mice) was done by two-tailed t test, and
for comparing several groups (WT, PS1 and PS1/APP
mice) and ages we used one-way ANOVA, followed by
Bonferroni post hoc multiple comparison test (SigmaStat
2.03, SPSS Inc). For both tests, the significance was set at
95% of confidence.
Results
Amyloid plaque-associated dystrophic neurites display
a massive accumulation of autophagic vesicles
from early ages
This PS1/APP transgenic model exhibited extracellular Ab
deposits throughout the hippocampus from a very early age
as illustrated in Fig. 1a with Congo red staining at 4 months.
The number and size of the amyloid deposits progressively
increased with age (Fig. 1b). In young mice (4- to 6-month
old), the most abundant plaques were those less than
500 lm2 (70.53 ± 9.74%), whereas in older mice
(18 months) the vast majority of plaques (69.41 ± 11.73%)
were medium to large ([500 lm2).
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Double labeling APP/Congo red (Fig. 1a–c) and APP/
thioflavin-S (Fig. 1d) experiments demonstrated that, at
every age examined, almost all (91.61 ± 0.14%, the per-
centage was practically identical at 4, 6 and 18 months of
age) fibrillar amyloid deposits were decorated with clusters
of APP-positive dystrophic neurites (APP is a well-repor-
ted marker for dystrophies) from the time of the appearance
of amyloid plaques. The number of dystrophic neurites per
plaque increased with age in parallel with the size of the
plaque (Fig. 1e). Results showed that, in fact, the number
of these dystrophic neurites correlated with the size of the
plaque and was independent of the age of the mice. Thus,
neuronal pathology in the form of dystrophic neurites
occurred very early in this transgenic model. These path-
ological structures were not found in wild-type (WT) or
PS1 transgenic mice of the same age (data not shown).
Therefore, plaque-associated abnormal swelling of neuro-
nal processes represented an early indicator of disease
development and might compromise neuronal integrity and
hippocampal function in young PS1/APP mice. No dys-
trophic neurites were found in areas remote from Ab
plaques or in 2-month-old PS1/APP mice (before the Ab
deposition).
Transmission electron microscopy analysis of the hip-
pocampus of 4.5-month-old PS1/APP mice revealed a
close spatial association between amyloid plaques and
neuronal dystrophies (Fig. 2a, b). No dystrophic neurites
were found in areas remote from plaques. These abnormal
swollen neurites had a round/oval profile and were giant-
sized, compared to normal neuronal processes in the
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Fig. 1 Early plaque-associated
neuritic dystrophy pathology in
PS1/APP hippocampus. a and
b APP-immunolabeled sections
counterstained with Congo red
for fibrillar amyloid deposits at
4 (a) and 6 (b) months of age
showing the early occurrence of
the neuritic pathology. The
number of neuritic plaques
progressively increases with
age. APP-positive dystrophic
neurites arise from
glutamatergic neurons since the
human APP transgene is
exclusively expressed by
principal neurons as shown in
the inset. c A representative
neuritic plaque formed by a core
of congophilic fibrillar amyloid
surrounded by numerous APP-
positive dystrophic neurites.
d Confocal image showing
APP-positive dystrophic
neurites (red) around a plaque
stained with thioflavin-S
(green). e Stereological
quantification of the dystrophic
neurites around plaques. The
number of dystrophies/plaque
increased with the size of plaque
(lm2). Data are expressed as
mean ± SD, *p \ 0.05. Scale
bars a and b 500 lm, inset
25 lm, c and d 10 lm.
CA1–CA3 subfields of the
hippocampus proper,
DG dentate gyrus
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adjacent neuropil. Ultrastructural morphometric analysis
(100 aberrant neurites; n = 3) revealed that the predomi-
nant size of these dystrophic structures was between 10 and
50 lm2 (63.74%), followed by those ranging from 50 to
100 lm2 (20.43%). Notably, 5% of the dystrophic neurites
measured over 100 lm2, only 9.68% of neurites were in the
range 5–10 lm2 and just 1% under 5 lm2. In contrast,
normal non-dystrophic neurites had an average size of
1.42 ± 0.77 lm2.
Dystrophic neurites were massively filled with collec-
tions of vacuolar structures of putative autophagic nature
with different morphologies and heterogeneous intralumi-
nal contents (Fig. 2c, e). The most common morphology
corresponded to autophagic vesicles (AVs) consisting of
double membrane-bound vesicles with densely compacted
amorphous or multilamellar contents named as auto-
phagosomes (Fig. 2c, d). These AVs represent the initial
stages of autophagy which contain undigested compacted
organellar material. In addition, there were also single or
double membrane vesicles with translucent or amorphous
electron-dense material in some dystrophic neurites
(Fig. 2e, f), and these might presumably represent auto-
phagosomes with partially digested material and/or the
mature degradative forms of AVs (autophagolysosomes).
Overall, a substantial accumulation of early and, to a less
extent, late AVs within hippocampal aberrant neurites,
surrounding amyloid plaques, occurred at very early ages
in these PS1/APP mice.
LC3-positive autophagic vesicles within dystrophic
neurites are implicated in the amyloidogenic pathway
To corroborate the autophagic nature of the heterogeneous
vesicles accumulated within the dystrophic neurites, we
immunostained PS1/APP hippocampal sections with the
anti-LC3 antibody, a marker of autophagy (Fig. 3a, b). At
4 months (Fig. 3a), LC3 immunoreactivity was mainly
found in pyramidal somata and their apical dendrites, as
well as in punctate structures resembling dystrophic neu-
rites around plaques (see insets in Fig. 3a). At 6 months
(Fig. 3b), the immunoreactivity for LC3 around plaques
was markedly increased while, in parallel, the staining of
somata and apical dendrites decreased.
To more specifically determine the proportion of LC3
that was in the LC3-II form, which migrates faster than
LC3-I on SDS-PAGE and is the form associated (by lipi-
dation) with the autophagosomal structures, we performed
quantitative immunoblot analysis of LC3-I and LC3-II
forms in the hippocampus of 6-month-old PS1/APP and
WT mice (Fig. 3c). Significantly higher levels of LC3-II
were observed in PS1/APP mice than in age-matched WT
mice (2.15 ± 0.35 fold, n = 6, p \ 0.05).
Confocal imaging of double APP/LC3 immunolabeling
(Fig. 3d1–d3) revealed the punctate nature of the LC3
labeling (see inset in Fig. 3d2) and the colocalization of
LC3 in both APP-positive (glutamatergic) and non-APP
(likely GABAergic or cholinergic) dystrophic neurites
(Fig. 3d3). Considering the colocalization of APP and LC3
within dystrophic neurites in our AD model, we next
wanted to assess the early implication of AVs in APP
processing, and in turn likely involvement in Ab produc-
tion. To that end, we performed immunoelectron
*
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Fig. 2 Extensive accumulation of autophagic vesicles within dystro-
phic neurites around amyloid plaques. Transmission electron
microscopy images of plaque-associated aberrant neurites in young
PS1/APP hippocampus. a Low magnification image of an amyloid
plaque (asterisk) surrounded by dystrophic neurites (discontinuous
white circles). b A diversity of dystrophic neurites based on their
subcellular content can be identified. c and d Dystrophic neurite filled
with heterogeneous electrodense double-membrane vesicles (white
square magnified in d) belonging to the early degrading autophagy-
lysosomal pathway (autophagosomes); these AVs had a dense
compacted amorphous (filled white arrows) or multilamellar content
(empty white arrows). e and f Dystrophic neurite filled with
autophagic vesicles (white square magnified in f) of distinct
morphologies showing translucent (filled white arrows) or amorphous
electrodense material (empty white arrows) which might represent
late autophagic vesicles (autophagolysosomes). Scale bars a 10 lm,
b 2 lm, c and e 1 lm, d and f 500 nm
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microscopy for APP and Ab42 in 4.5-month-old PS1/APP
hippocampus. Silver-enhanced immunogold labeling
revealed that APP localized preferentially to the AVs
within plaque-associated dystrophic neurites (Fig. 3e–g),
as well as to the Golgi and endoplasmic reticulum (ER)
membranes in the neuronal cell somata (Fig. 3h). No APP-
labeling was found in other organelles or plasma mem-
brane. Immunoelectron microscopy detection of Ab was
much less stronger than of APP, since optimal intracellular
labeling with the antibodies for Ab forms in our model
requires pre-treatment with formic acid which is not
compatible with EM processing. Nevertheless, as expected
and in contrast to APP immunolabeling, Ab42 label was
mainly associated with plaques (asterisk in Fig. 3i). Inter-
estingly, some autophagic vesicles within dystrophic
neurites were also positive for the Ab42 antibody (inset in
Fig. 3i).
Dystrophic neurites represent axonal structures
with cytoskeletal abnormalities
To determine the dendritic and/or axonal nature of the
plaque-associated dystrophic neurites in our PS1/APP
model, we have performed light and electron microscopy
studies in 4- to 6-month-old mice. Immunolabeling for the
MAP-2 protein (a marker of dendritic processes) (Fig. 4a,
b) and for the postsynaptic marker a1GABAAR (not
shown) revealed no positive dystrophic neurites around
plaques at the early ages investigated. Moreover, confocal
double MAP-2/APP immunofluorescence labeling con-
firmed the lack of colocalization for the dendritic marker in
APP-positive dystrophic neurites (Fig. 4c1–c3). On the
other hand, the close spatial relationship between amyloid
plaques and axonal fibers tracts in the hippocampus, as
revealed by neurofilament (NF) immunolabeling and
Congo red staining (Fig. 4d), along with the presence of
swollen NF-positive neurites (insets in Fig. 4d) indicated a
possible axonal/synaptic origin of these dystrophic
structures.
In fact, the labeling of the dystrophic neurites was very
patent with the presynaptic marker synaptophysin
(Fig. 4e). Numerous synaptophysin-positive punctated
structures were observed around amyloid plaques. To
determine the neurochemical nature of these synapto-
physin-positive dystrophic neurites, we performed double
immunofluorescence labeling for APP and the two major
neurotransmitter vesicular transporters, VGLUT1 for glu-
tamate (Fig. 4f1–f3) and VGAT for GABA (Fig. 4g1–g3).
As shown in Fig. 4f3 most APP-positive dystrophic neu-
rites contained VGLUT1 indicating the glutamatergic
nature of the abnormal axons surrounding amyloid plaques.
Consistent with the exclusive expression of the human
mutated transgene for APP by principal cells, many
enlarged inhibitory GABAergic dystrophic neurites, im-
munonegative for APP, were also identified around the
plaques (Fig. 4g3).
In addition, electron microscopy in the hippocampus of
4.5-month-old PS1/APP mice confirmed the presence of
some dystrophic myelinated axons around/near plaques
(Fig. 4h–j). These axonal dystrophies had a severe
(Fig. 4h, i) to moderately (not shown) pathological number
of autophagic vesicles. The enlarged size of an aberrant
axon (110.22 lm2) compared to adjacent normal ones
(1.57 ± 0.63 lm2) is shown in Fig. 4j.
In order to identify possible early microtubule-associated
axonal transport deficits in the PS1/APP hippocampus,
which might lead to vesicle accumulation (autophagic,
synaptic, etc.) along axons and the consequent development
of dystrophy, we first assessed tau abnormalities by quanti-
tative Western blots experiments with the AT8 antibody
(which detects tau phosphorylated at both serine 202 and
threonine 205 residues, one of the first to be phosphorylated)
(Fig. 5a). Immunoblotting revealed a significantly higher
level of expression in young PS1/APP mice (1.75 ± 0.15
fold) compared to age-matched controls. We have also
confirmed by AT8 immunohistochemistry the presence of
phospho-tau positive neurites surrounding amyloid plaques
in 4- to 6-month-old transgenic animals (Fig. 5b). To
determine whether phospho-tau was present within APP-
positive dystrophic neurites, we performed double APP/AT8
immunofluorescence labeling (Fig. 5c1–c4 and d1–d4). The
presence of AT8 was found in some, but not all, APP-posi-
tive dystrophic neurites (Fig. 5c3 and detail in c4; Fig. 5d3
and detail in d4).
Tau could also induce changes in the organization and
stability of neuronal actin filaments, and it is known that
the formation of cofilin/actin pathological bundles occludes
neurites and vesicle transport. To assess possible early
alterations of the actin cystoskeleton in our AD model we
analyzed actin and cofilin immunolabeling in the hippo-
campus of young PS1/APP mice. Results showed
numerous rod-like inclusions around amyloid plaques as
shown for cofilin in Fig. 5e. Moreover, double APP/cofilin
labeling (Fig. 5f1–f3) showed colocalization of both
markers in some, particularly small, APP-positive neurites.
Finally, to further explore whether microtubule vesicu-
lar transport was compromised in young PS1/APP mice we
measured the levels of kinesin-1 and dynein, two micro-
tubule-associated motor proteins, in hippocampal protein
extracts prepared from 6-month-old PS1/APP and WT
mice (Fig. 5g). We found significantly lower levels of both
kinesin-1 heavy chain (-24.71 ± 11.80%, n = 8) and
dynein (-38.06 ± 14.40%, n = 8) in PS1/APP than age-
matched WT animals.
These microtubule, actin cytoskeletal and molecular
motor defects are early pathogenic events in our AD model
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and might lead to transport abnormalities and the accu-
mulation of organelles (synaptic vesicles, autophagosomes,
mitochondria, lysosomes) within axonal neurites promot-
ing the dystrophic process.
The early axonal pathology includes morphologically
disrupted presynaptic terminals
The axonal defects in our AD model could also affect
presynaptic terminals. Therefore, in order to investigate
the possible early synaptic pathology we examined the
hippocampus of 4.5-month-old PS1/APP mice using
electron microscopy (Fig. 6a–e). Our ultrastructural study
showed that, near to amyloid plaques, there were pre-
synaptic elements that displayed pathological changes
including large diameter with a considerate number of
AVs and, in contrast, fewer synaptic vesicles (Fig. 6a, b;
presynaptic terminals outlined with a white line). The
presence of presynaptic terminals, at the beginning of the
dystrophy process, with few and early stage AVs for-
mation, as well as with synaptic-like vesicles were also
detected (Fig. 6c–e; see also the presynaptic terminal
outlined with a black line in Fig. 6b). However, these
altered presynaptic elements were making synaptic
contacts with morphologically normal dendrites or den-
dritic spines with postsynaptic density (see Fig. 6a–d).
These morphologically altered presynaptic terminals may
represent the initial stages of synaptic disruption and
loss.
Moreover, we compared the LC3-II accumulation in
synaptosomal and microsomal fractions isolated from
6-month-old WT and PS1/APP animals (Fig. 6f). As
expected, a low percentage of LC3-II was observed in
isolated synaptosomes from WT mice (15.42 ± 2.25%,
n = 4, of microsomal fractions in WT mice). Further, in
agreement with our electron microscopy studies, the
amount of LC3-II in PS1/APP mice was higher in both
synaptosomal and microsomal fractions. Although the
relative abundance of LC3-II presented in PS1/APP-
derived synaptosomes was still low (22.22 ± 3.84% of
PS1/APP microsomal LC3-II), the level was consistently
higher (2.54 ± 0.54, n = 5) than in WT synaptosomes.
These data demonstrated the existence of an early
autophagy-associated axonal/synaptic pathology in the
hippocampus of this AD mouse model.
Extracellular periplaque oligomeric Ab spatially
correlates with axonal/synaptic dystrophy
Taking into account the close spatial relationship
between axonal dystrophies and Ab plaques, we next
examined the possible intracellular and/or extracellular
origin of the pathogenic Ab agent. We first investigated
the possible intracellular accumulation of oligomeric Ab
in isolated synaptosomes and microsomes by immuno-
precipitation experiments using the monoclonal antibody
6E10 (Fig. 7a). Results demonstrated the presence of a
relatively large accumulation of monomeric Ab in syn-
aptosomes, whereas lower levels were detected in
microsomes (Fig. 7a1). Furthermore, within the different
Ab peptides, the Ab42 was the major form observed in
these synaptosomal fractions (Fig. 7a2). On the other
hand, no Ab oligomers were observed with this
approach.
We have also used the anti-oligomeric Ab antibody A11
in immunohistochemistry and immunoprecipitation exper-
iments. Our results demonstrated that most Ab plaques were
immunopositive for the A11 antibody (Fig. 7b), with a
preferential immunolabeling at the plaque periphery (see
inset). Furthermore, A11-immunoprecipitation using the
soluble (S1) fractions demonstrated the presence of minute
amount of extracellular oligomeric Ab (Fig. 7c) in the
hippocampus of the PS1/APP mice at this early age
(6 months). These data were consistent with previous
experiments (see also [29, 30]). However, in spite of the
relative abundance of monomeric Ab in synaptosomes,
under the present experimental conditions, no Ab oligomers
Fig. 3 Autophagic compartments within dystrophic neurites are sites
of APP processing. a and b Immunohistochemistry for the auto-
phagosome marker LC3 in CA1 subfield of PS1/APP mice
hippocampus. At 4 months (a), immunoreactivity was concentrated
in pyramidal cell somata (stratum pyramidale) and their apical
dendrites (stratum radiatum). LC3-positive dystrophic neurites were
surrounded amyloid plaques (upper inset in a) and were punctate in
nature (the lower inset shows a high magnification image of the LC3-
positive dystrophy circled in the upper inset). At 6 months (b), the
immunoreaction was mainly associated with dystrophic neurites
around plaques (arrows) as shown here for stratum oriens (SO).
c Quantitative immunoblot analysis of LC3-II form in the hippocam-
pus of 6-month-old PS1/APP and WT mice. PS1/APP mice had
significantly higher LC3-II levels than age-matched WT mice (n = 6,
p \ 0.05). d1–d3 Confocal images of double immunofluorescence
labeling for APP (green) and LC3 (red); APP-positive dystrophic
neurites around an amyloid plaque (asterisk) displayed the LC3
marker (long arrows); some LC3-positive dystrophic neurites were
negative for APP (short arrows) indicating the non-glutamatergic
origin of these aberrant neurites. e Dystrophic neurites (encircled)
around amyloid plaques (asterisk) were APP immunopositive as
revealed by electron microscopy using silver-enhanced immunogold
labeling. f Higher magnification of a dystrophic neurite immunopos-
itive for APP; small open squares indicate mitochondria; inset shows
two autophagosomes immunogold-labeled for APP. g Higher mag-
nification image of two autophagic vesicles immunogold-labeled for
APP. h In addition to autophagic vesicles, APP immunogold labeling
was associated with the endoplasmic reticulum (ER) and Golgi
cisternae in neuronal somata. i Immunogold labeling revealed that
Ab42 peptides localize to amyloid plaques (asterisk) and autophagic
vesicles (inset). so stratum oriens, sp stratum pyramidale, sr stratum
radiatum. Scale bars a and b 100 lm (upper inset in a 50 lm, lower
inset in a 10 lm); d1–d3 100 lm (inset in d2 2.5 lm), e–h 500 nm,
inset in f 200 nm, i 2 lm and inset 400 nm
b
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were detected in this fraction (Fig. 7c). On the other hand,
in the microsomal fractions, in the A11 immunoprecipita-
tion experiments many non-specific bands were observed.
The presence of this non-specific immunoprecipitation
precluded the identification of putative oligomers. It is
possible that the relative high abundance of AVs in this
fraction could interfere with the immunoprecipitation
experiments. Aiming to overcome this problem, the pres-
ence of the possible oligomers was also assayed using
Western blots with 6E10 and 82E1 antibodies. The 6E10
antibody produced no specific signal (not shown); the 82E1
antibody, however, produced a clear specific (as compared
with age-matched WT results) identification of Ab oligo-
mers (Fig. 7d). Taken together, these data indicate the
presence of Ab monomers in synaptosomes and Ab oligo-
mers in extracellular plaques and the microsomal fractions.
Discussion
Here we report data showing that amyloid plaques are
associated with dystrophies of axonal origin (loaded with
autophagic vesicles) and constitute a very early patholog-
ical event in the hippocampus of PS1M146L/APP751SL mice.
The presence of morphologically disrupted presynaptic
terminals may be one of the initial stages for synaptic loss
and dysfunction, so far the best correlate for early symp-
toms in AD patients [3, 9, 19, 41, 45, 52, 53, 59, 61] and,
therefore, a pre-clinical manifestation of progression of the
disease.
Amyloid accumulation is considered a key event in AD
pathology by causing glial activation, neuritic alteration,
synaptic damage and neuronal death [34, 35, 42]. All the
fibrillar amyloid deposits in the hippocampus of our trans-
genic mice were identified as human-like neuritic plaques
with dystrophic neurites and reactive gliosis. Dystrophic
neurites are classically associated with compacted plaques in
AD tissue [21, 24, 25, 39, 40, 57, 58] and these neuritic
plaques have been considered to be a pathological correla-
tion of dementia in AD patients [43]. Though neuritic
dystrophy may apply to both dendritic and axonal morpho-
logical changes, in our model the predominant axonal nature
of the dystrophies was demonstrated by colocalization with
common axonal/synaptic (neurofilament, synaptophysin,
VGLUT1 and VGAT) but not dendritic (MAP-2,
a1GABAAR) markers. Furthermore, assessment of the
dystrophies using electron microscopy also confirmed their
axonal structure. Notably, a thorough examination of dys-
trophic neurites at the electron microscopic level revealed
that they were not postsynaptic to any presynaptic bouton
(not shown in results). Although we cannot rule out the
existence of dendritic alterations, in our model most dys-
trophies displayed an axonal origin. The presence of axonal
dystrophies has been reported in AD patients in both early
and late stages of the disease [7, 21, 22, 57] and also in
another AD models [1, 8, 14, 20, 49, 64].
As found in the brains of people with AD [47, 66]
and in other transgenic models [65, 66], in our PS1/APP
model the axonal dystrophies were seen to have a large
accumulation of a great variety of vesicles in the process
of autophagy. Autophagy, an efficient cellular degrada-
tion and maintenance pathway for multiple components,
is not usually observed in normal brains. Recently, it has
been demonstrated that PS1 mutations accelerate the
pathogenesis of AD by impairing autophagy and orga-
nelle turnover, since PS1 is essential for autolysosome
acidification and maturation [37]. The critical contribu-
tion of defective autophagy proteolytic clearance to the
Ab pathology has been recently demonstrated in
TgCRND8 transgenic mice [65]. Restoring the autoph-
agy-lysosomal pathway by deletion of cystatinB in these
AD mice reduced intracellular and extracellular amyloid
load, and rescued memory performance. The existence of
autophagic pathology in hippocampal dystrophic neurites
in our PS1/APP model was evidenced at early ages
Fig. 4 Dystrophic neurites are of axonal origin. a MAP-2 (dendritic
marker) and Congo red staining in the hippocampus of 6-month-old
PS1/APP mice (arrows indicate amyloid plaques). b No dystrophic
neurites immunopositive for MAP-2 were seen around amyloid
plaques, as illustrated here for a Congo red stained amyloid plaque
(asterisk) embedded in a MAP2-positive neuropil in the radiatum
layer. c1–c3 Confocal double immunofluorescence labeling for MAP-
2 (red) and APP (green) revealed no colocalization of the two
markers (asterisk indicates an amyloid plaque). d Strong overlapping
in the location of hippocampal axonal pathways and amyloid plaques
as shown here using neurofilament (NF) immunolabeling and Congo
red staining. Axonal dystrophies were observed around congophilic
plaques as shown in the larger inset, and a detail of an axonal
swelling is shown in the smaller inset. e Neuritic dystrophies around
plaques (asterisk) were immunopositive for synaptophysin (arrows).
f1–f3 Confocal laser double immunofluorescence labeling for APP
(red) and VGLUT1 (green) shows extensive colocalization (arrows)
of the two markers indicating the axonal glutamatergic nature of APP-
positive dystrophic neurites around plaques (asterisk). g1–g3 Double-
label immunofluorescence confocal laser microscopy for APP (red)
and VGAT (green) shows the existence of GABAergic axonal
dystrophies (VGAT-positive and APP-negative; arrows) around
amyloid plaques (asterisk). h–j Transmission electron microscopy
images. h Low magnification image of an amyloid plaque (asterisk)
surrounded by dystrophic neurites. i At a higher magnification, detail
of the dystrophic myelinated axon circled in h; the inset shows the
autophagic vesicle content of this axonal swelling and the myelin
sheath. j Another representative image of a myelinated axonal
swelling, filled with autophagic vesicles. The giant size of this
dystrophy could be estimated by comparison with the adjacent normal
myelinated axonal profiles; inset shows a detail of this axonal
dystrophy. CA1–CA3 subfields of the hippocampus proper. DG
dentate gyrus, sp stratum pyramidale, sl stratum lucidum. Scale bars
a 250 lm, b 25 lm, c1–c3 15 lm, d 500 lm (larger inset 50 lm and
smaller inset 5 lm), e 20 lm, f1–f3 and g1–g3 10 lm, h 20 lm,
i 2 lm (inset 200 nm), j 2 lm (inset 500 nm)
b
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Fig. 5 Cytoskeletal pathology in young PS1/APP hippocampus.
a Quantitative Western blotting using AT8 antibody in the hippo-
campus of 6-month-old PS1/APP and WT mice; PS1/APP mice had
significantly higher AT8 levels than to age-matched WT mice (n = 6,
p \ 0.05). b The presence of AT8-positive structures around plaques
(asterisk) was observed from 4 months of age. c1–c4 and d1–d4.
Double-label immunofluorescence confocal laser microscopy of APP
(green) and AT8 (red) in 6-month-old transgenic mice showing the
presence of phospho-tau in some APP-positive dystrophic neurites.
e Immunohistochemistry for cofilin revealed the presence of actin–
cofilin rods around plaques (asterisk) from 4 months of age. A higher
magnification detail of a rod is shown in the inset. f1–f3 Confocal
laser microscopy with double APP/cofilin labeling revealed the
presence of cofilin within some APP-positive neurites. g Quantitative
Western blotting for heavy chain kinesin-1 and dynein in 6-month-old
PS1/APP and WT mice hippocampus. PS1/APP mice were found to
have significantly lower kinesin-1 and dynein levels than age-
matched WT mice (n = 8, p \ 0.05). Scale bars b 100 lm, c1–c3
5 lm, c4 2.5 lm, d1–d3 7.5 lm, d4 2.5 lm, e 50 lm (inset 7 lm),
f1–f3 7.5 lm
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(4–6 months) by increased protein levels of the marker
of autophagosome formation LC3-II, by specific immu-
nolocalization of LC3 in the axonal dystrophies,
surrounding plaques, and by electron microscopy mor-
phological identification of the AVs that were completely
filling the axon and causing the local axonal swelling.
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Fig. 6 Autophagy pathology correlates with aberrant presynaptic
terminals. a–e Transmission electron microscopy images of aberrant
axon terminals (outlined with white lines) containing autophagic
vesicles and making asymmetric contact with normal postsynaptic
elements (asterisks the postsynaptic densities are indicated with black
arrows). a and b Severely disrupted presynaptic terminals (white
lines) containing numerous autophagic vesicles and apparently no
synaptic vesicles. A presynaptic element (outlined with black lines)
that contains one autophagy vesicle (indicated with white arrow), near
to the active zone is shown in b. c and d Presynaptic terminals in a
probable initial stage of the dystrophy development, were character-
ized by the accumulation of relatively few autophagic vesicles (white
arrows) and many synaptic vesicles. e Presynaptic terminal showing a
putative phagophore (PA) engulfing synaptic-like vesicles, as well as
an autophagosome containing mitochondria (open arrow) and few
autophagic vesicles containing degraded material (white arrows).
f Quantitative immunoblot analyses of the LC3-II form in micro-
somes and synaptosomes from 6-month-old PS1/APP and WT mice.
LC3-II accumulated in both microsomal and synaptosomal fractions
of WT and PS1/APP hippocampus, though a predominant localization
was found in the microsomal fraction. The levels of LC3-II in WT
synaptosomes were extremely low, as compared with microsomes
(please note the different scale bars). Although in PS1/APP most
LC3-II was also present in microsomes, the relative accumulation was
more patent in synaptosomes (as compared with WT). The relative
abundance of LC3-II in each fraction was normalized by the values
for WT microsomal fractions. ATPsynthase and b-actin were used as
markers of purity in the isolation procedure and protein loading,
respectively. m mitochondria. Scale bars a 1 lm, b–e 500 nm
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This agreement between different mice models and AD
cases strongly support the involvement of autophagy in
the development of AD.
Intact microtubules are needed for AVs transport and
their clearance, facilitating fusion between autophago-
somes and late endosomal and lysosomal compartments
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Fig. 7 Monomeric Ab
accumulates in isolated
synaptosomes whereas Ab
oligomers are present in the
plaque periphery and
microsomes. a The Ab content
were analyzed by 6E10
immunoprecipitation and
Western blots (16%-Tris-
Tricine-SDS-PAGE) in
synaptosomal and microsomal
fractions from 6-month-old WT
and PS1/APP mice (a1) or by
82E1 Western blots after urea-
SDS-PAGE (16%) in PS1/APP
synaptosomal fractions (a2). As
shown, the monomeric Ab was
predominantly enriched in the
synaptosomal fractions (a1).
From the different Ab peptides,
the Ab42 was the predominant
form found in synaptosomes
(a2). b Oligomeric Ab peptides
were localized at the periphery
of the plaques by
immunohistochemistry with the
A11 antibody. Inset shows a
higher magnification of an
immunostained amyloid plaque.
c The presence of oligomeric
Ab in extracellular soluble
fractions (S1), synaptosomes
and microsomes was assessed
by immunoprecipitation
experiments, using the A11
antibody, and Western blots
(6E10) using 12%-Tris-Glycine-
SDS-PAGE. In agreement with
a putative plaque origin, Ab
oligomers (57, 90 and 96 kDa)
were identified in S1 fractions.
d Representative Western blot
of WT and PS1/APP
microsomal fractions using the
mAb 82E1. As shown, Ab
oligomers (ranging Mr
30–60 kDa) were clearly
identified using this antibody.
CA1–CA3 subfields of the
hippocampus proper, DG
dentate gyrus. Scale bars
b 250 lm (inset 25 lm)
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thus preventing the accumulation of immature AVs in
neurites [11, 33, 36]. Supporting the possible involvement
of microtubule destabilization in AD pathogenesis, it has
been recently reported [31] that natural oligomeric Ab,
isolated from AD patients, disrupted the microtubule
cytoskeleton and caused neuritic dystrophy (see also [67]).
This effect seemed to be mediated by tau hyperphosph-
orylation at Ser202/Ser205 (AT8 epitope). In fact, tau
reduction prevents Ab-induced impairment of axonal
transport [63]. Interestingly, it has been just reported that
disease-associated changes in tau conformation inhibit
kinesin-dependent axonal transport by modulating axonal
phosphotransferases [32]. In line with this our data indi-
cated the existence of early defective axonal transport
within dystrophic axons in our transgenic model. These
dystrophic neurites displayed tau phosphorylation (AT8-
positive) and actin–cofilin rods, and both alterations are
known to alter cytoskeletal dynamics in neurons (revised in
[6]). Moreover, both the kinesin-1 and dynein levels were
significantly reduced and, although non-significantly at
6 months of age, neurofilaments (H and M chains) were
phosphorylated (not shown). Taken together, our current
results suggest that early tau phosphorylation produced
axonal transport defects leading to AV accumulation and
neurite pathology.
A relevant issue is the pathogenic signal behind this tau
and transport dysregulation. The density and size of the
neuritic plaques in our transgenic model increased in an age-
dependent manner while the number of the associated dys-
trophic neurites was strongly related to the plaque size. The
relationship between formation of extracellular amyloid
deposits and their associated dystrophies remains elusive.
Whereas some authors have proposed that the appearance of
dystrophic neurites precedes plaque formation [2, 23, 27,
56], a recent study using in vivo multiphoton imaging
showed that dystrophies develop following amyloid depo-
sition [42]. Supporting the later notion, in our AD model the
onset of dystrophic neurites occurred in parallel to the for-
mation of amyloid plaques, and most (if not all) dystrophic
neurites were associated with Ab plaques. Furthermore, we
have also observed plaque-associated axonal dystrophies in
GABAergic and cholinergic neurons ([5, 44, 51]; this work,
see Fig. 4g, and unpublished results). These neurons did not
express the transgenic APP and, consequently, did not
accumulate intracellular Ab [5, 44, 51]. Thus, the formation
of the dystrophic neurites in these neurons might be induced
by extracellular Ab, in close proximity to plaques. In con-
trast, the high content of APP within the dystrophic neurites
suggests a possible direct role of such malformations in
plaque formation. Increasing evidence implicates axons as
an important source of extracellular amyloid deposits [68]
and synaptic activation promotes amyloid secretion, whereas
chronic reduction of synaptic activity was found to reduce
plaque loading in an AD transgenic mouse model [15, 16,
60]. Interestingly, in our transgenic model, hippocampal
plaque deposition is tightly linked to axonal pathways, as
seen by simultaneous Congo red staining and neurofilament
immunostaining. This agrees with the idea of Ab released by
axonal terminals and the consequent formation of extracel-
lular deposits. In any case, the two processes, plaque
induction of neuritic changes and a contribution of dystro-
phic neurites to Ab deposition are not mutually exclusive and
could occur concomitantly.
The soluble forms of oligomeric amyloid peptides are of
special interest to play a significant role in AD pathology.
Soluble Ab oligomers have been shown to induce an
increase in tau hyperphosphorylation [17, 31] as well as
severe axonal transport failure and disruption of organelle
trafficking through GSK3-beta signalling (manuscript in
preparation;[18, 31]). Furthermore, we have recently
reported [30] the involvement of natural and synthetic Ab
oligomers in the activation of GSK3-beta and tau phos-
phorylation. Thus, it is tempting to speculate that Ab
oligomers, acting through a yet unidentified mediator,
caused the interruption of axonal transport, accumulation
of vesicles and axonal dystrophy.
The extracellular or intracellular origin of these soluble
amyloid oligomers has not yet been well defined. In
relation to this, as recently reported in AD cases [55], the
results we report here demonstrate that PS1/APP synap-
tosomes accumulate Ab peptides (Ab42 the most
abundant). However, these Ab peptides were in mono-
meric form and no oligomers were detected at this age.
On the other hand, we also identified, by immunogold
labeling, the presence of APP and Ab42 in AVs which
agrees with the participation of the autophagic compart-
ments in APP processing and Ab production, as described
by others [65, 66]. We also found that AVs were mainly
accumulated in the microsomal fractions and, although
the Ab seemed to be produced principally in the synap-
tosomes, Ab oligomers were identified in these
microsomal fractions. These results provide evidence for
the idea that the AVs, within the axonal dystrophies, are a
possible compartment for Ab oligomerization. On the
other hand, taken together, the close temporal and spatial
association between amyloid plaques and dystrophic
neurites, the presence of A11-positive Ab oligomers in
the plaque periphery and the Ab oligomers in the soluble
fractions suggested that plaques also might be a source of
the Ab oligomers that could induce neuritic damage. In
support of this idea, amyloid fibrils, major component of
amyloid plaques, can be destabilized and easily reverted
to soluble and highly toxic Ab aggregates by biological
lipids that are present in the brain [38] and, as mentioned
above, GABAergic cells (that did not express hAPP and
did not accumulated Ab peptides) also displayed axonal
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dystrophies. In any case, further experiments are needed
to clarify this point.
A further significant result was the identification by
electron microscopy of dystrophic axon terminals that were
making contact with morphologically normal postsynaptic
elements. These abnormal presynaptic boutons contained
numerous AVs and were observed to have a low content in
synaptic vesicles. These results were confirmed by LC3-II
Western blots using synaptosomes isolated from the hippo-
campus of 6-month-old PS1/APP mice. Although we cannot
rule out a direct effect of soluble Ab on these presynaptic
terminals, their relative distance from Ab plaques (between
10 and 30 lm) together with the low soluble Ab content at
this age, suggested that AV accumulation might reflect the
axonal transport defects at dystrophies. These altered syn-
aptic terminals may represent one of the initial pathogenic
steps of synaptic loss leading to early deficits in synaptic
transmission and plasticity.
As early memory loss in AD is increasingly attributed to
synaptic failure, we can conclude that this PS1/APP
transgenic model shows, at young ages and in absence of
pyramidal degeneration, a presynaptic pathology progres-
sion that may closely resemble the pre-clinical or early
stages of human AD.
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